# Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

> **NCT02945852** · PHASE2 · COMPLETED · sponsor: **Fan Yun, MD** · enrollment: 40 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** apatinib

## Key facts

- **NCT ID:** NCT02945852
- **Lead sponsor:** Fan Yun, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-11-15
- **Final completion:** 2019-05-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02945852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02945852, "Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02945852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*